295 related articles for article (PubMed ID: 34921025)
1. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
[TBL] [Abstract][Full Text] [Related]
2. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
[TBL] [Abstract][Full Text] [Related]
3. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
[TBL] [Abstract][Full Text] [Related]
4. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
[TBL] [Abstract][Full Text] [Related]
6. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
[TBL] [Abstract][Full Text] [Related]
7. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
[TBL] [Abstract][Full Text] [Related]
8. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
Chen Q; Jia G; Zhang X; Ma W
Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
[TBL] [Abstract][Full Text] [Related]
9. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
[TBL] [Abstract][Full Text] [Related]
10. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Lim SM; Kim CG; Lee JB; Cho BC
Cancer Discov; 2022 Jan; 12(1):16-19. PubMed ID: 35022206
[TBL] [Abstract][Full Text] [Related]
11. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
12. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
[TBL] [Abstract][Full Text] [Related]
13. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.
Polonio-Alcalá E; Porta R; Ruiz-Martínez S; Vásquez-Dongo C; Relat J; Bosch-Barrera J; Ciurana J; Puig T
Biomed Pharmacother; 2022 Dec; 156():113942. PubMed ID: 36411628
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.
Lim SM; Kim CG; Cho BC
Cancer Res; 2022 Jan; 82(1):18-20. PubMed ID: 34983785
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
19. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
20. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Patel SA; Nilsson MB; Yang Y; Le X; Tran HT; Elamin YY; Yu X; Zhang F; Poteete A; Ren X; Shen L; Wang J; Moghaddam SJ; Cascone T; Curran M; Gibbons DL; Heymach JV
Clin Cancer Res; 2023 Apr; 29(7):1292-1304. PubMed ID: 36595561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]